Core Viewpoint - 4DMedical has successfully raised over $100 million (approximately AUD 150 million) in a new round of institutional funding, aimed at accelerating the deployment of its core product CT:VQ™ in the U.S. market and enhancing R&D investments to solidify its technological advantage in software-based pulmonary imaging [1][2]. Financing Purpose: Systematic Investment for "Scaled Deployment" - The funding will focus on commercial expansion within U.S. academic medical centers and large health systems, promoting the use of CT:VQ in multidisciplinary settings such as radiology and respiratory departments [3]. - The company aims to strengthen customer success, training, and technical support systems to help hospitals integrate CT:VQ into existing imaging workflows, increasing sustained usage rather than remaining at a single-point deployment [3]. - Continuous R&D investment will enhance 4DMedical's capabilities in functional lung imaging, expanding its product portfolio and deepening its platform, thereby increasing the technical barriers in software-based pulmonary assessment [3]. - Post-financing, 4DMedical reported a cash position exceeding $130 million (approximately AUD 200 million), supporting its U.S. expansion strategy and growing installed base [3]. What is CT:VQ: Enabling Lung Function Assessment with Conventional CT - CT:VQ is 4DMedical's core product, a software that provides lung ventilation-perfusion (V/Q) functional imaging based on conventional chest CT, delivered via a SaaS model [4]. - Unlike traditional V/Q imaging that relies on nuclear medicine or enhanced scans, CT:VQ uses non-enhanced chest CT data to generate quantitative ventilation and perfusion results, providing functional information that conventional CT cannot directly offer [5]. - CT:VQ can be integrated into existing hospital imaging infrastructures without the need for new scanning equipment, allowing for rapid deployment leveraging the extensive CT installed base in the U.S. [5]. Financing Progress: Deployment in Top Medical Centers within 4 Months - 4DMedical highlighted the rapid deployment of CT:VQ, which was installed in several top U.S. academic medical centers, including Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health, within just four months post-FDA approval [7]. - This adoption pace reflects the genuine demand from clinicians for "quantitative, actionable, functional imaging information" and indicates a high level of maturity in IT integration and workflow adaptation for CT:VQ [7]. Commercialization Conditions: FDA Approval, Payment Pathways, and Ecosystem Collaboration - CT:VQ has received FDA 510(k) approval, making it the first and currently the only non-enhanced V/Q imaging technology based on CT globally [9]. - The product has been confirmed for reimbursement under the U.S. Medicare system, allowing for additional payment under Category III CPT codes, which provides a commercial basis for integration into routine clinical operations [10]. - 4DMedical's product is designed for seamless integration with existing hospital infrastructures, and the company has established a partnership with Philips to support broader market outreach [10]. Conclusion - The recent funding round is significant for 4DMedical, reflecting market recognition of its technology and the CT:VQ product, as well as the commercial progress and growth potential achieved in the U.S. market [11]. - With institutional funding and a stronger balance sheet, 4DMedical plans to continue expanding the clinical adoption of CT:VQ, accelerate R&D efforts, deepen partnerships, and advance its global footprint in software-based pulmonary imaging [11][12].